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Abstract 
Background: Bacillus cereus is one of the pathogens causing nosocomial bloodstream infections (BSIs). However, 
few reports have documented the antimicrobial susceptibility and clinical characteristics of Bacillus cereus BSI and the 
importance of empirical therapy. The aim of this study was to investigate the clinical characteristics and antimicrobial 
susceptibility of B. cereus isolates from patients with BSI and to analyze the impact of appropriate empirical therapy on 
the outcome of patients with B. cereus BSI.
Methods: All adult cases of bacteremia between April 2003 and March 2012 in a teaching hospital in Tokyo, Japan 
were reviewed retrospectively. Clinical data were collected from the patients’ medical records and charts. Antimicro-
bial susceptibility testing was performed by broth microdilution method. The patients with B. cereus BSI were divided 
into an appropriate empirical therapy group and an inappropriate empirical therapy group. The primary outcome was 
all-cause mortality at 4 weeks after the start of BSI. The secondary outcome was early defervescence within 2 days 
after starting empirical therapy.
Results: There were 29 B. cereus bloodstream infection cases. No vancomycin, gentamicin, and imipenem-resistant 
isolates were found. However, 65.5 % were resistant to clindamycin and 10.3 % were resistant to levofloxacin. The main 
etiology was venous catheter-related (69 %). All-cause mortality at 4 weeks was not significantly different between 
the appropriate empirical therapy group (9 cases) and the inappropriate group (20 cases) in this study. However, early 
defervescence within 2 days after starting empirical therapy was significantly different (p = 0.032).
Conclusions: The BSI of B. cereus is mostly caused by venous catheter-related infections. Appropriate empirical 
therapy is important to achieve early clinical resolution in B. cereus BSI. Vancomycin is one of the appropriate selec-
tions of empirical therapy for B. cereus BSI.
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Background
The Bacillus cereus group contains six species, B. cereus, 
B. thuringiensis, B. weihenstephanensis, B. mycoides, B. 
pseudomycoides, and B. anthracis [1]. The most preva-
lent human pathogen in the B. cereus group is B. cereus 
[1]. The automated identification system in diagnostic 
laboratories cannot distinguish between B. cereus and B. 
thuringiensis, because they are genetically similar species. 
However, B. thuringiensis is an extremely rare human 
pathogen and is basically an insect pathogen [2].
B. cereus is a spore-forming Gram-positive bacillus 
that exists ubiquitously in soil, marine environments, 
vegetables, the intestinal tracts of invertebrates, and 
human skin [3]. The organism is a common pathogen 
in food poisoning [3]. Invasive B. cereus infections such 
as bacteremia, pneumonia [4], eye infection [5], central 
nervous system (CNS) infections [6, 7], and soft tissue 
infections [8, 9] have been reported in hospital settings. 
More information about the clinical characteristics of 
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B. cereus bloodstream infection (BSI) is urgently needed 
to improve the treatment of patients with B. cereus 
infection.
BSIs are important causes of morbidity and mortality. 
Appropriate empirical therapy should be started imme-
diately after BSI is identified [10]. Recent reports have 
analyzed risk factors for B. cereus BSI, such as prior anti-
microbial treatment [11, 12], reuse of contaminated tow-
els [13, 14], central venous catheter insertions [12, 15], 
and hematological malignancy [16]. Fatal outcomes have 
been related to neutropenia [6], delays in treatment [17], 
and CNS symptoms [15, 17].
Inappropriate antibiotic therapy has been shown to 
be predictive of higher mortality rates in patients with 
bacteremia compared to appropriate therapy [10]. The 
antimicrobial agents for the empirical therapy should 
be selected according to the antimicrobial susceptibility 
of the pathogen. However, few studies have reported on 
the clinical characteristics of B. cereus BSI and the impor-
tance of empirical therapy [17, 18]. The aim of this study 
was therefore to investigate the antimicrobial susceptibil-
ity of clinical B. cereus isolates from patients with BSI and 
to analyze the impact of appropriate empirical therapy on 
clinical outcomes in patients with B. cereus BSI.
Methods
Study setting and patients
All cases of bacteremia that occurred between April 2003 
and March 2012 in the microbial blood culture database 
of the University of Tokyo Hospital, a 1217-bed tertiary-
care teaching hospital in Tokyo, Japan, were retrospec-
tively reviewed. Patients with B. cereus bacteremia were 
divided into appropriate empirical therapy and inappro-
priate empirical therapy groups.
Data collection and definitions
All adult (age ≥18 years) patients from whose blood cul-
tures B. cereus was isolated were enrolled. Bacteremia 
caused by B. cereus was defined as: (1) two or more posi-
tive blood cultures collected in one day; or (2) positive 
blood cultures collected on more than two consecutive 
days. Untreated cases and cases that received oral antimi-
crobial therapy were excluded, as were patients who were 
afebrile despite positive blood cultures for B. cereus.
Patients’ data, clinical symptoms, laboratory results, 
antibiotics used, in-hospital mortality due to any cause, 
presence of blood cultures that became negative, and 
microbiological data were collected from the clini-
cal charts and the laboratory database. Patients’ data 
included age, sex, underlying disease (diabetes mellitus, 
cirrhosis, malignancy, immunosuppressants, and neu-
tropenia), and implanted medical devices such as cen-
tral venous catheters, biliary stents, and artificial joints. 
Clinical symptoms included fever, suspected focus of 
infection, and complications with BSI. Laboratory data 
were white blood cell counts, neutrophil counts, C-reac-
tive protein and albumin levels. Data of antibiotics used 
before and after blood culture samples were obtained 
were also reviewed.
Fever was defined as a body temperature ≥37.5  °C. 
When a body temperature of <37.5  °C was maintained 
for >24 h, the patient was defined as afebrile. Body tem-
perature was measured at least 3 times a day (at 08:00, 
14:00, and 20:00). A complication was considered a focus 
of infection accompanied by B. cereus BSI.
Empirical therapy was defined as the antibiotics 
received on the first day of therapy for the BSI. Appropri-
ate antimicrobial therapy was defined as systemic admin-
istration of at least one antimicrobial agent to which the 
B. cereus isolate proved susceptible in vitro.
Microbiological methods
Blood culture specimens were inoculated into BACTEC 
standard culture bottles in a BACTEC 9000 system (Bec-
ton, Dickinson and Company, Franklin Lakes, NJ, USA). 
All isolates were identified as B. cereus/B. thuringiensis 
using a VITEK2 system with the BCL card (SYSMEX 
bioMerieux, Tokyo, Japan). Antimicrobial susceptibil-
ity was determined with the Walkaway system and the 
standard criteria of the Clinical and Laboratory Stand-
ards Institute (CLSI) guide. The breakpoints against B. 
cereus in the CLSI guideline M45A2E [19] were used for 
the following agents: ampicillin, cefazolin, cefotaxime, 
caftazidime, imipenem, vancomycin, amikacin, gen-
tamicin, erythromycin, levofloxacin, clindamycin, chlo-
ramphenicol and rifampin. For other antimicrobials, the 
breakpoints for Staphylococcus spp. in the CLSI guideline 
M 100-S22 [20] and S24 [21] were used [22].
Clinical outcomes
The primary outcome was all-cause mortality at 4  weeks 
after onset of bacteremia. The secondary outcome was early 
defervescence within 2 days after starting empirical therapy.
Statistical analysis
Fisher’s exact test was used for analysis of categori-
cal data. Non-parametric data were analyzed using the 
Mann–Whitney U test. Values of P < 0.05 were consid-
ered significant. All statistical analyses were performed 




A total of 5894 cases with positive blood cultures was 
identified over the 9-year study period. Of these, B. 
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cereus was isolated in 203 cases. One hundred sev-
enty one cases were excluded, because they had one B. 
cereus-positive blood culture. Three cases with more 
than two B. cereus-positive blood cultures were also 
excluded, because one case was untreated, one case was 
treated with oral antibiotics, and one case was afebrile. 
After applying the exclusion criteria, 29 cases (14.3  % 
of cases in which B. cereus was detected, 0.49  % of all 
culture-positive cases) were included in this study. The 
patients’ clinical characteristics are shown in Table  1. 
The mean age was 65.3  years (range 18–89  years), and 
55.2  % were male. The main etiology was venous cath-
eter-related (69  %). The appropriate and inappropriate 
empirical therapy groups had similar baseline character-
istics, sources of infection, and comorbidities that could 
significantly affect the clinical outcome. Complications 
except focuses of infection cited in Table 1 was endoph-
thalmitis (1 case) occurred in the inappropriate empiri-
cal therapy group. In laboratory results, patients in the 
appropriate therapy group had a tendency to have higher 
white blood cell counts than patients in the inappropri-
ate therapy group.
Antimicrobial susceptibility
All isolates showed sensitivity to vancomycin, gen-
tamicin, and imipenem. However, 48.3–100 % of isolates 
were resistant to cephalosporins, 65.5  % were resistant 
to clindamycin, and 10.3 % were resistant to levofloxacin 
(Table 2).
Antibiotic treatment
In the appropriate empirical therapy group, piperacillin-
tazobactam (3 cases), vancomycin (2 cases), or ampi-
cillin–sulbactam, cefmetazole, clindamycin, amikacin, 
or cefoperazone–sulbactam (1 case each) was used. In 
the inappropriate empirical therapy group, cefepim (6 
cases), ampicillin–sulbactam, cefazolin, ceftriaxone/cefo-
taxim (3 cases each), ceftazidime (2 cases), cefotiam, or 
clindamycin (1 case each) was used, and in vitro testing 
showed that the B. cereus isolated on blood culture was 
resistant. One patient was not treated empirically with 
antibiotics. The duration of antimicrobial therapy did not 
differ between the two groups (Table 3). All patients, but 
one, were changed to an appropriate antibiotic agent by 
5 days.
Table 1 Characteristics of patients with Bacillus cereus bloodstream infection
a Other sources of BSI in the inappropriate empirical therapy group include febrile neutropenia (2 cases), possible infective endocarditis according to modified Duke’s 
criteria (2 cases), and peritonitis (1 case)
Variable All patients (n = 29) Empirical therapy that was deemed P value
Appropriate (n = 9) Inappropriate (n = 20)
Age, years (median, range) 65.3 (18–89) 68 (18–89) 65 (47–83) 0.743
Sex (male/female) 16/13 4/5 12/8 0.688
No. of patients with comorbidity
 Diabetes mellitus 8 3 5 0.675
 Malignancy 15 4 11 0.700
 Liver cirrhosis 4 1 3 1.00
 Immunosuppressant 5 2 3 0.633
 Neutropenia 4 0 4 0.280
No. of patients with implanted device
 Central venous catheter 6 1 5 0.633
 Peripheral venous catheter 22 8 14 0.382
 Others 7 3 4 0.642
Source of BSI
 Total catheter-related infection 20 7 13 0.675
  Peripheral blood catheter 15 6 9 0.427
  Central venous catheter 5 1 4 1.00
 Othersa 5 0 5 0.153
 Unknown 4 2 2 0.568
Laboratory data (average, range)
 White blood cell count (/μL) 7497 (100–22,200) 9630 (1800–22,200) 6537 (100–16,100) 0.052
 C-reactive protein (g/dL) 4.19 (0.04–16.6) 3.79 (0.04–16.6) 3.34 (0.17–13.7) 0.514
 Albumin (g/dL) 3.29 (2.10–4.20) 2.71 (2.10–3.90) 3.45 (2.40–4.20) 0.206
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Clinical outcome
In terms of the primary outcome, no significant dif-
ference in all-cause mortality at 4  weeks after onset 
of bacteremia was seen between the groups (Table  3). 
However, the secondary outcome of early deferves-
cence was achieved significantly more often in the 
appropriate empirical therapy group. Central venous 
catheters were all removed in both groups. The pres-
ence of blood cultures that became negative was con-
firmed in 6 patients of the appropriate therapy group 
and 17 patients of the inappropriate therapy group. 
However, the intervals of taking blood cultures differed 
depending on the cases.
Discussion
The present data show that the BSI of B. cereus was 
mostly caused by venous catheter-related infections 
and that appropriate empirical therapy is important to 
achieve early clinical resolution in B. cereus bloodstream 
infection, although the appropriateness of therapy does 
not affect mortality.
In this study, cases detected B. cereus in more than two 
sets of blood cultures were enrolled as definite BSI and 
accounted for 14.3 % of B. cereus-detected cases. In our 
hospital, the rate of obtaining two sets of blood cultures 
was around 60  % at the beginning of the study period, 
and it increased to 75  % at the end. Although a further 
Table 2 Antimicrobial susceptibility of major antibiotics against Bacillus cereus
a Minimum inhibitory concentration
b MIC at which 50 or 90 % of tested isolates are inhibited
c This isolates were interpreted as “not susceptible” because the breakpoint was only set for susceptible
Antimicrobial agent n MICa (mg/dL) Interpretation n (%)
Range 50 %b 90 %b Susceptible Interpretive Resistant
Vancomycin 29 ≤2 ≤2 ≤2 29 (100) 0 0
Imipenem 29 ≤0.5 to 4 ≤0.5 ≤0.5 29 (100) 0 0
Gentamicin 29 ≤2 to 4 ≤2 4 29 (100) 0 0
Amikacin 26 ≤16 ≤16 ≤16 26 (100) 0 0
Linezolid 25 ≤0.25 to 2 1 1 25 (100)
Chloramphenicol 22 2 to 4 4 4 22 (100) 0 0
Rifampin 15 ≤1 ≤1 ≤1 15 (100) 0 0
Levofloxacin 29 ≤0.12 to >16 ≤0.5 ≤0.5 26 (89.7) 1 (3.4) 2 (6.9)
Clindamycin 29 <0.25 to ≥4 2 2 10 (34.5) 18 (62.1) 1 (3.4)
Erythromycin 29 ≤0.25 to >16 0.5 1 18 (62.1) 6 (20.7) 2 (6.9)
Cefazolin 29 ≤8 to ≥64 ≤8 15 (51.7) 6 (20.7) 8 (27.6)
Daptomycin 22 ≤0.12 to 4 2 4 8 (36.4) 12 (54.5)c
Cefotaxime 22 4 to ≥64 16 32 2 (9.1) 18 (81.8) 2 (9.1)
Ampicillin/sulbactam 25 ≤0.25 to >8 4 >8 1 (4) – 24 (96)
Ampicillin 29 0.5 to >8 >4 >4 0 – 29 (100)
Ceftazidime 22 32 to >64 >64 >64 0 0 22 (100)
Table 3 Antibiotic empirical therapy and outcomes of Bacillus cereus bloodstream infection
* Statistically significant (p < 0.05)
a One patient was excluded in this analysis because of transfer to another hospital
Variable All patients (n = 29) Empirical therapy that was deemed P value
Appropriate (n = 9) Inappropriate (n = 20)
Duration of appropriate antibiotic  
treatment median (days, range)
15 (7–41) 13 (7–20) 16.5 (7–41) 0.050
Early defervescence (patients) 10 6 4 0.032*
Survival at 4 weeks (patients) 27a 8/9 (88.9 %) 19/19 (100 %) 0.321
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increase of the two-set rate may enable us to obtain 
more cases and uncover the detailed clinical picture of 
B. cereus BSI, the criterion used to select the definitive B. 
cereus BSI cases was more than two sets of positive blood 
cultures according to the BSI guideline [23]. B. cereus 
bacteremia was reported to be underestimated as con-
tamination [24, 25], and it has recently been increasingly 
recognized that some cases of B. cereus bacteremia are 
definite BSIs [15, 17].
Bacteremia due to other bacteria, such as Staphylococ-
cus aureus and extended-spectrum beta lactamase-pro-
ducing Gram-negative bacteria, caused higher 30-day 
mortality in patients with various comorbidities than B. 
cereus bacteremia even when empirical therapy was inap-
propriate [26, 27]. In the present study, only one patient 
died in the appropriate therapy group, and no patient 
died in the inappropriate therapy group, indicating that 
B. cereus might be less virulent to humans. However, the 
appropriateness of therapy still has benefit for patients 
with B. cereus BSI, because early defervescence was sig-
nificantly related to appropriate empirical antibiotic 
therapy.
Which antibiotic agents are appropriate for bacteremia 
due to B. cereus? In the present study, the B. cereus iso-
lated was frequently not susceptible to empirical therapy, 
but an early treatment response was related to suscepti-
ble empirical therapy.
In this study, all isolates were resistant to ampicillin, 
and almost all were resistant to cephalosporins. All were 
sensitive to carbapenems. This could be explained by 
the fact that B. cereus is genetically resistant to all beta-
lactams except carbapenems [3]. However, some reports 
showed carbapenem-resistant B. cereus bacteremia [28, 
29], and some in vitro studies showed that B. cereus pos-
sesses metallo-beta lactamase genetically [30, 31]. Thus, 
further study is needed to determine whether carbapen-
ems could be one of the choices for empirical treatment 
of B. cereus BSI.
Fluoroquinolones and clindamycin are also possible if 
a B. cereus isolate is susceptible. The present data showed 
a resistance rate of 65.5 % (19/29 cases) for clindamycin 
and 10.3  % (3/29) for levofloxacin. Horii et  al. reported 
that 26 B. cereus isolates from blood cultures showed 
MIC90 of levofloxacin as 4 (CLSI’s breakpoint of levo-
floxacin was ≤2 as sensitive) [11]. When empirical ther-
apy is started with these agents, the susceptibility pattern 
should be considered.
All isolates showed good susceptibility to vancomycin 
according to CLSI’s breakpoint (MIC ≤4 as sensitive). 
Other reports [11, 22] also showed no vancomycin-
resistant B. cereus isolated from both clinical samples 
and environmental samples. Given that a main cause 
of B. cereus BSI is catheter-related infection, vancomy-
cin is suitable for empirical treatment of B. cereus BSI, 
because the common causative pathogens of catheter-
related infection are Gram-positive bacteria including S. 
aureus and coagulase-negative Staphylococci. However, 
BSI caused by B. cereus with vancomycin-reduced sus-
ceptibility (MIC 4 μg/mL) was reported in neonates [32]. 
We should pay attention to changes in susceptibility to 
vancomycin.
Other optimal choices for Gram-positive bacteria, dap-
tomycin and linezolid, are options in B. cereus BSI. In the 
present study, the MIC90 of linezolid was 1, and all iso-
lates were considered susceptible. In contrast, more than 
half of the B. cereus showed the MIC of daptomycin >1, 
although breakpoint of daptomycin was ≤1 as suscepti-
ble. The MIC of daptomycin was tested by microdilution 
assay. Luna et  al. [22] reported that the MICs of dapto-
mycin were 0.25–1 using the E test for 42 strains of B. 
cereus collected from the environment. The differences in 
the MICs might be due to differences in methodology or 
differences in whether they were clinical isolates or not. 
An in vitro study reported that a gene that gave daptomy-
cin resistance was activated under swarming condition 
[33], and that spores were resistant to daptomycin until 
they germinated [34]. Thus, further study of the measure-
ment of daptomycin MIC and the use of daptomycin for 
treatment is needed.
This study has some limitations. First, whether anti-
microbials were susceptible was determined by anti-
microbial breakpoints of B. cereus in CLSI’s guideline 
M45A2E [19]. However, for some antimicrobials for 
which breakpoints have not been determined, break-
points of S. aureus in M100 [21] were used with refer-
ence to a previous report [22]. Although breakpoints 
of these species were similar for various classes of anti-
microbials such as cephalosporins, vancomycin was 
slightly different. This may be limitation of this study 
because undefined breakpoints of B. cereus may differ 
from those of S. aureus already defined in M100 [21]. 
We hope that various antimicrobial breakpoints of B. 
cereus would be set based on the abundant experience 
with the treatment of B. cereus infection. Second, B. 
cereus and B. thuringiensis were not distinguished in 
this study, because the automated identification sys-
tem was used. Although B. thuringiensis is basically a 
harmless pathogen to humans, the extremely rare case 
with B. thuringiensis infection might have been missed. 
Third, the study was performed retrospectively based 
on clinical records, and the number of cases was small. 
To determine the most effective therapy for B. cereus 
BSI, more large-scale and prospective studies should be 
performed.
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Conclusions
The definite BSI of B. cereus accounted for 14.3 % of B. 
cereus-detected cases, and they were mostly caused by 
venous catheter-related infections. Early clinical resolu-
tion was related to appropriate empirical antibiotic ther-
apy. Vancomycin is optimal for empirical therapy of B. 
cereus BSI, but further clinical data are needed.
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